| | | | |
CUSIP No. 29014R103 | | Schedule 13G | | Page 5 of 9 |
ITEM 1. | (a) Name of Issuer: |
Eloxx Pharmaceuticals, Inc. (the “Issuer”).
| (b) | Address of Issuer’s Principal Executive Offices: |
950 Winter Street, Waltham, Massachusetts 02451
ITEM 2. | (a) Name of Person Filing: |
Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:
Gurnet Point L.P.
Waypoint International GP LLC
Waypoint International Holdings S.A.
Ernesto Bertarelli
| (b) | Address or Principal Business Office: |
The business address of each of Gurnet Point L.P. and Waypoint International GP LLC is 55 Cambridge Parkway, Suite 401, Cambridge, MA 02142. The business address of each of Waypoint International Holdings S.A. and Mr. Bertarelli is Av. Giuseppe Motta 31-33, PO Box 145, CH-1211, Geneva 20, Switzerland.
| (c) | Citizenship of each Reporting Person is: |
Each of Gurnet Point L.P. and Waypoint International GP LLC is organized under the laws of Delaware. Waypoint International Holdings S.A. is organized under the laws of Switzerland. Mr. Bertarelli is a Swiss citizen.
| (d) | Title of Class of Securities: |
Common stock, par value $0.01 per share (“Common Stock”).
29014R103
Not applicable.